| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| P2093 | author name string | Mojgan Ahmadzadeh | |
| P2860 | cites work | Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease | Q73542905 |
| Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma | Q74535384 | ||
| T cell memory | Q74578125 | ||
| A novel transcription factor, T-bet, directs Th1 lineage commitment | Q22253874 | ||
| Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death | Q24563654 | ||
| Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 | Q24672849 | ||
| Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes | Q24676216 | ||
| Two subsets of memory T lymphocytes with distinct homing potentials and effector functions | Q28146072 | ||
| Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease | Q28202655 | ||
| Regulation of immune responses by TGF-beta | Q28271433 | ||
| Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells | Q28305879 | ||
| CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs | Q28594485 | ||
| The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells | Q29614226 | ||
| TGF-beta signaling in tumor suppression and cancer progression | Q29615427 | ||
| Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer | Q29616379 | ||
| Effects of TGF-beta on the immune system: implications for cancer immunotherapy. | Q33713481 | ||
| Chemokines in tissue-specific and microenvironment-specific lymphocyte homing | Q33898971 | ||
| Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells | Q34094070 | ||
| Progress in human tumour immunology and immunotherapy | Q34253585 | ||
| Transforming growth factor-beta in T-cell biology | Q34572232 | ||
| Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination | Q34648472 | ||
| Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma | Q36119828 | ||
| Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth | Q36351780 | ||
| Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha | Q36353974 | ||
| Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor | Q36368533 | ||
| Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation | Q36369726 | ||
| Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients | Q36551911 | ||
| A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance | Q37699443 | ||
| Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine | Q40662562 | ||
| Status of activation of circulating vaccine-elicited CD8+ T cells | Q40864307 | ||
| Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. | Q40968846 | ||
| Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes | Q41054119 | ||
| Transforming growth factor-beta and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype | Q41135213 | ||
| Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells | Q41494312 | ||
| Transforming growth factor beta and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site | Q41854472 | ||
| Elevated plasma levels of transforming growth factor (TGF)-β1 and TGF-β2 in patients with disseminated malignant melanoma | Q42858939 | ||
| Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. | Q45885336 | ||
| Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression | Q53717569 | ||
| Differential expression of transforming growth factor beta 1 and interleukin 10 in progressing and regressing areas of primary melanoma. | Q54644576 | ||
| Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors | Q68748541 | ||
| Tumor-specific cytolysis by lymphocytes infiltrating human melanomas | Q69738303 | ||
| Production of multiple cytokines by cultured human melanomas | Q71619623 | ||
| Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 | Q72052802 | ||
| Single IL-2-secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine secretion phenotype | Q72727383 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5215-5223 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells | |
| P478 | volume | 174 |
| Q36990620 | 'Yin-Yang' functions of transforming growth factor-beta and T regulatory cells in immune regulation |
| Q36743890 | A Novel Mechanism of PPARgamma Regulation of TGFbeta1: Implication in Cancer Biology |
| Q40081629 | Adoptive transfer of cytotoxic T-cells for treatment of residual disease after irradiation |
| Q52353619 | Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts |
| Q28390573 | Anti-tumor immunity: Myeloid leukocytes control the immune landscape |
| Q34720223 | Antitumor effects and mechanisms of dendritic cells stimulated by sCD40L on ovarian cancer cells in vitro |
| Q33637647 | Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells |
| Q33714522 | CD4(+)CD25(+) T regulatory cells inhibit CD8(+) IFN-gamma production during acute and chronic FIV infection utilizing a membrane TGF-beta-dependent mechanism |
| Q45865376 | Cancer gene therapy: the power of negative thinking |
| Q35598951 | Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose irradiation |
| Q92963134 | Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy |
| Q53636593 | Clonal restriction of the expansion of antigen-specific CD8+ memory T cells by transforming growth factor-{beta}. |
| Q33688619 | Combination epidermal growth factor receptor variant III peptide-pulsed dendritic cell vaccine with miR-326 results in enhanced killing on EGFRvIII-positive cells |
| Q42144694 | Cytomegalovirus and Tumors: Two Players for One Goal-Immune Escape |
| Q38260051 | Designing effective vaccines for colorectal cancer. |
| Q35931423 | Detection and Characterization of a Novel Subset of CD8+CD57+ T Cells in Metastatic Melanoma with an Incompletely Differentiated Phenotype |
| Q39882336 | Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response |
| Q42380337 | Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors |
| Q38045235 | From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation |
| Q36909362 | Genetic modification of T cells for immunotherapy |
| Q37790599 | Harnessing the immune response to treat cancer |
| Q34276831 | Human CCR4+ CCR6+ Th17 cells suppress autologous CD8+ T cell responses |
| Q36327148 | IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells |
| Q36959201 | Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation |
| Q35711576 | Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma |
| Q38608340 | Immunological hallmarks of stromal cells in the tumour microenvironment |
| Q30443888 | Immunological profiling of a panel of human ovarian cancer cell lines |
| Q29636247 | Immunosuppressive strategies that are mediated by tumor cells |
| Q51615623 | Impaired T cell function in malignant pleural effusion is caused by TGF-β derived predominantly from macrophages |
| Q91708036 | Impairment of NKG2D-Mediated Tumor Immunity by TGF-β |
| Q90043623 | In Vitro and Ex Vivo Models - The Tumor Microenvironment in a Flask |
| Q47721380 | Lower TGFß serum levels and higher frequency of IFNγ‐producing T cells during early immune reconstitution in surviving children after allogeneic stem cell transplantation |
| Q35186471 | Mammary gland involution as an immunotherapeutic target for postpartum breast cancer. |
| Q36490750 | Mechanisms of immune evasion by tumors |
| Q36983409 | Negative regulators in homeostasis of naïve peripheral T cells. |
| Q59327125 | Non-hematopoietic Control of Peripheral Tissue T Cell Responses: Implications for Solid Tumors |
| Q42786561 | Nonredundant roles of IL-10 and TGF-β in suppression of immune responses to hepatic AAV-factor IX gene transfer |
| Q41911200 | Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD8+ T cells |
| Q34976602 | Programming CD8+ T cells for effective immunotherapy. |
| Q52715799 | Regulatory T Cells As Potential Targets for HIV Cure Research. |
| Q36609898 | Review article: immune suppression and colorectal cancer |
| Q37044604 | Role of TGF-β and the tumor microenvironment during mammary tumorigenesis |
| Q51183547 | SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. |
| Q34259098 | Secretion of immunoregulatory cytokines by mesenchymal stem cells. |
| Q38225334 | Stromal fibroblasts and the immune microenvironment: partners in mammary gland biology and pathology? |
| Q37087603 | Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy |
| Q34343664 | T Cells and Stromal Fibroblasts in Human Tumor Microenvironments Represent Potential Therapeutic Targets |
| Q36334023 | T cell immune reconstitution following lymphodepletion. |
| Q33722462 | TGF-beta and regulatory T cell in immunity and autoimmunity |
| Q36020084 | TGF-beta and tumors--an ill-fated alliance |
| Q40247364 | TGF-beta inhibition of CTL re-stimulation requires accessory cells and induces peroxisome-proliferator-activated receptor-gamma (PPAR-gamma). |
| Q36402151 | TGF-beta modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression |
| Q40347818 | TGF-beta, T-cell tolerance and immunotherapy of autoimmune diseases and cancer |
| Q28263622 | TGF-beta: a mobile purveyor of immune privilege |
| Q39155158 | TGF-β Family Signaling in Tumor Suppression and Cancer Progression. |
| Q55515390 | TGF-β in T Cell Biology: Implications for Cancer Immunotherapy. |
| Q35145392 | Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression |
| Q93169928 | Targeting small molecule drugs to T cells with antibody-directed cell-penetrating gold nanoparticles |
| Q37175025 | Targeting tumors with LIGHT to generate metastasis-clearing immunity |
| Q89587246 | The Intestinal Tumour Microenvironment |
| Q24310157 | The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer |
| Q34309388 | The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors |
| Q37454364 | The polarization of immune cells in the tumour environment by TGFbeta |
| Q42333838 | The tumor microenvironment disarms CD8+ T lymphocyte function via a miR-26a-EZH2 axis |
| Q63407070 | Transforming Growth Factor-β Signaling in Immunity and Cancer |
| Q33712568 | Transforming growth factor beta (TGF-beta) and inflammation in cancer |
| Q34240499 | Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression |
| Q36801053 | Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers |
| Q40117564 | Transforming growth factor-beta1 suppresses hepatitis B virus replication primarily through transcriptional inhibition of pregenomic RNA. |
| Q36516410 | Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer |
| Q33661529 | Two faces of TGF-beta1 in breast cancer |
| Q94546919 | Upregulated MELK Leads to Doxorubicin Chemoresistance and M2 Macrophage Polarization via the miR-34a/JAK2/STAT3 Pathway in Uterine Leiomyosarcoma |
| Q49545801 | α4β7+ CD4+ effector/effector memory T cells differentiate into productively and latently infected central memory T cells by TGFβ1 during HIV-1 infection. |
Search more.